
















BMJ Open Population-based cancer incidence and mortality rates and ratios among adults with intellectual disabilities in Scotland: a retrospective cohort study with record linkage

Laura McKernan Ward ^{1,2}, Sally-Ann Cooper ², Filip Sosenko ², David Morrison ², Michael Fleming ², Colin McCowan ³, Katie Robb ⁴, Catherine R Hanna ⁵, Laura Hughes-McCormack ², Kirsty Dunn ², David Conway ⁶, Angela Henderson ², Gill Smith ², Maria Truesdale ², Deborah Cairns ²

To cite: Ward LMCK, Cooper S-A, Sosenko F, *et al.* Population-based cancer incidence and mortality rates and ratios among adults with intellectual disabilities in Scotland: a retrospective cohort study with record linkage. *BMJ Open* 2024;**14**:e084421. doi:10.1136/bmjopen-2024-084421

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<https://doi.org/10.1136/bmjopen-2024-084421>).

Received 18 January 2024

Accepted 19 July 2024

ABSTRACT

Objective To provide contemporary data on cancer mortality rates within the context of incidence in the population with intellectual disabilities.

Methods Scotland's 2011 Census was used to identify adults with intellectual disabilities and controls with records linked to the Scottish Cancer Registry and death certificate data (March 2011–December 2019). The control cohort without intellectual disabilities and/or autism were used for indirect standardisation and calculation of crude incident rates/crude mortality rates, and age–sex standardised incident rate ratios/standardised mortality ratios (SIR/SMR), with 95% CIs. **Results** Adults with intellectual disabilities were most likely diagnosed cancers of digestive, specifically colorectal (14.2%), lung (9.3%), breast (female 22.9%), body of the uterus (female 9.3%) and male genital organs (male 17.6%). Higher incident cancers included metastatic cancer of unknown primary origin (female SIR=1.70, male SIR=2.08), body of uterus (female SIR=1.63), ovarian (female SIR=1.59), kidney (female SIR=1.85) and testicular (male SIR=2.49). SMRs were higher, regardless of a higher, similar or lower incidence (female SMR=1.34, male SMR=1.07). Excess mortality risk was found for colorectal (total SMR=1.54, male SMR=1.59), kidney (total SMR=2.01 u, female SMR=2.85 u), female genital organs (SMR=2.34 (ovarian SMR=2.86 u, body of uterus SMR=2.11), breast (female SMR=1.58) and metastatic cancer of unknown primary origin (female SMR=2.50 u, male SMR=2.84).

Conclusions Adults with intellectual disabilities were more likely to die of cancer than the general population. Reasons for this may include later presentation/diagnosis (so poorer outcomes), poorer treatment/compliance or both. Accessible public health approaches are important for people with intellectual disabilities, and healthcare professionals need to be aware of the different cancer experiences faced by this population.

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ Our key strength is the comprehensive coverage of administrative and health records identifying the population with and without intellectual disabilities.
- ⇒ By using nationwide robust data linkage of high-quality electronic health records, we provide reliable data with minimal bias.
- ⇒ Limitations include our inability to account for cancer incidence before the census date, which was mitigated against by our well-powered person-time for rate calculation, allowing for a meaningful interpretation of mortality rates in the context of incidence.
- ⇒ Death certificate data imprecision is considered, but our dual-analysis (underlying cause and all-cause analyses), mitigates differences and indeed have similar interpretations.

INTRODUCTION

Intellectual disabilities are a group of conditions with significant limitations in intellectual functioning and adaptive behaviour, with onset in childhood affecting 1.4% of the world population.¹ People with intellectual disabilities continue to face substantial health inequalities culminating in a 20 year premature mortality gap,² and a higher proportion of avoidable deaths compared with the general population.^{3 4} One of the most common avoidable mortalities is cancer, as many cancers are considered either preventable or treatable.⁵ However, there lacks robust comparative studies of cancer incidence and mortality between the population with and without intellectual disabilities. This is crucial, as healthcare assumptions based on



© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Laura McKernan Ward;
lward001@dundee.ac.uk

general population evidence may not be applicable for the population with intellectual disabilities.

Cancer is a leading cause of mortality,⁶ but studies about people with intellectual disabilities show inconsistent findings. Cohort studies indicate a higher standardised mortality ratio (SMR) for people with intellectual disabilities compared with the general population,^{4 7 8} though some report no significant difference.⁹ The most common cancer-related deaths in the population with intellectual disabilities include respiratory (lung), digestive (colon) and breast cancers.^{7 10} Disparities compared with the general population were highest for digestive, metastatic cancer with unknown primary origin, bladder and cervical cancers (SMRs between 2 and 3); lip, oral cavity and pharynx, rectal, female genital organs, colon, oesophageal, haematopoietic, urinary, breast and pancreatic cancers (SMRs between 1 and 2). Cuyppers and colleagues found no cancers associated with a lower mortality rate.⁷ Specific data on stomach, liver, body of uterus, ovarian, testicular, kidney or brain cancers were not reported in this extensive work. Higher rates of colorectal cancer mortality have been reported in males (SMR=2.7), but not females with intellectual disabilities.⁹ Glover and colleagues reported that women with intellectual disabilities had greater risk of female genital organ cancer mortality (SMR=2.3); however, this was based on nine deaths split between cancer of the body of the uterus and ovary, with exact figures not reported.⁹ Unlike Cuyppers *et al*, non-significant SMRs for breast, lung and haematopoietic cancers were reported, and authors agreed that brain cancer was not significantly different in this population.⁹ A smaller study found no statistical differences in mortality from breast, lung and digestive cancers in adults with intellectual disabilities, perhaps due to the study size.¹¹ These conflicting results (with wide CIs, different cancer categories and varying age ranges), highlight the gaps in the scientific literature available on cancer mortality ratios in the population with intellectual disabilities.

Cancer mortality is the combination of cancer incidence (being diagnosed with cancer), survival rates and the occurrence of both cancer-related death and non-cancer-related death. Therefore, whether the reported higher SMRs are due to a higher incidence, later presentation or poorer care is yet to be determined. People with intellectual disabilities have distinctly different factors that could influence likelihood of cancer incidence; for example, a higher prevalence of obesity, gastro-oesophageal reflux disorder, exposure to helicobacter pylori infection, more sedentary behaviour and mobility problems, poorer diets and nulliparity, but a lower likelihood to smoke or drink alcohol excessively.¹² National studies consistently evidence lower screening programme participation in the population with intellectual disabilities,¹³ potentially impacting cancer rates.

The incidence of cancer in the population with intellectual disabilities appears to be lower in older adults,^{14 15} higher in children and young adults¹⁶ or the

same as in the general population for children and adults combined.^{17 18} However, methodological limitations exist in this evidence base, including retrospective study design (excluding people with incident cancer who died), inclusion of people with autism (who may have different health profiles) and sampling cohorts from those using support services or hospital discharge records.^{14–16} Similarly, identification via residential care received identified <35% of people with intellectual disabilities reported in Cuyppers and colleagues' mortality paper which used more extensive methods,¹⁹ and the authors confirm this likely focuses on people with more severe intellectual disabilities.⁷ Older studies from Patja and Sullivan and colleagues used more robust identification methods, and are better comparators for our results, despite identifying only 70% of the population via service-use.^{17 18} However, the data are more than 20 years old (1967–1997; 1982–1997), so may not reflect more recent cancer rates due to lifestyle changes (namely long-stay hospital closure and community care for adults with intellectual disabilities). However, the population with intellectual disabilities had higher incident cancers of gall bladder and thyroid cancers, and lower prostate and lung cancers.¹⁷ Leukaemia, corpus uteri and colorectal cancers were reported as higher in females with intellectual disabilities, leukaemia, brain and stomach cancers were more common in males with intellectual disabilities, while prostate cancer was less common.¹⁸ Each of these studies report a similar wide range of common cancer types, and except for a lower incidence of prostate cancer, the findings are contradictory.

The aim of this study was to describe both cancer incidence and mortality rates in people with intellectual disabilities at a population level using a large, nationwide cohort of adults of all ages with intellectual disabilities, compared with the general population.

METHODOLOGY

Data sources and study population

Population data from Scotland's 2011 Census linked to the National Records of Scotland (NRS) death certificate data and Scottish Cancer Registry (Scottish Morbidity Records 06, SMR06) held by National Services Scotland were used. As previously described,²⁰ linkage was undertaken for 94% of the Scottish population who completed Scotland's 2011 Census. The cohorts consisted of all adults with intellectual disabilities (with or without co-occurring autism aged 18+) as recorded within the Census, and a 15% randomly selected comparator sample from the general population who had neither intellectual disabilities nor autism. Record linkage between census and health records was successful for >92% of these two cohorts. We report cancer incidence and mortality for an 8year, 9month period from 28 March 2011 (1 day after Scotland's 2011 Census) to 31 December 2019 (prior to excess Covid-19 mortality and under-recorded cancer incidence). Cases who were alive at the end of the

Table 1 Demographic information for the whole cohort of adults (aged 18+, n=583 264) with and without intellectual disabilities (ID) and those with cancer diagnosis and/or cancer-related death (n=43 193)

Demographics	All adults		All adults with any cancer	
	ID, n (%)	GPop, n (%)	ID, n (%)	GPop, n (%)
Total	17 203	566 061	796	42 397
Sex				
Male	9565 (55.6)	267 157 (47.2)	389 (48.9)	19 583 (46.2)
Female	7638 (44.4)	298 904 (52.8)	407 (51.1)	22 814 (53.8)
Mean age at 2011 Census (SD)	43.9 (16.8)	49.0 (18.3)	58.4 (14.7)	63.5 (15.6)
Age categories				
18–24	2720 (15.8)	59 829 (10.6)	14 (1.8)	1045 (2.5)
25–34	2976 (17.3)	83 868 (14.8)	39 (4.9)	1606 (3.8)
35–44	3277 (19.1)	97 884 (17.3)	85 (10.7)	2371 (5.6)
45–54	3664 (21.3)	108 050 (19.1)	165 (20.7)	5331 (12.6)
55–64	2494 (14.5)	92 688 (16.4)	201 (25.2)	9764 (23.0)
65–74	1330 (7.7)	67 520 (11.9)	191 (24.0)	11 439 (27.0)
75+	742 (4.3)	56 222 (9.9)	101 (12.7)	10 841 (25.6)
SIMD quintile				
1-most deprived	4893 (28.4)	103 659 (18.3)	245 (30.8)	8412 (19.8)
2	4393 (25.5)	110 435 (19.5)	204 (25.6)	8665 (20.4)
3	3491 (20.3)	115 911 (20.5)	158 (19.8)	8568 (20.2)
4	2693 (15.7)	119 586 (21.1)	122 (15.3)	8646 (20.4)
5-least deprived	1733 (10.1)	116 470 (20.6)	67 (8.4)	8106 (19.1)
Living arrangements				
ID living with family carer	7337 (42.7)		187 (23.5)	
ID living alone (no family carer but with paid carer support)	4447 (25.8)		317 (39.8)	
ID living with partner and/or dependent child/ren without family carer	1049 (6.1)		61 (7.7)	
ID living in shared private household (with paid carer support)	1590 (9.2)		79 (9.9)	
ID living in communal establishment (with paid carer support)	2780 (16.2)		152 (19.1)	

GPop, general population; ID, intellectual disabilities; SIMD, Scottish Index of Multiple Deprivation.

study were censored on the study end date. This study excluded 30 cases from the general population who did not self-identify as having an intellectual disability in the Census record, but subsequently died during the study with one or more all-contributing factors relating to an intellectual disability or autism (ICD-10 codes F70, F71, F72, F73, F78, F79, F84). Self-reported data on biological sex at birth were taken from the Census but there were a small number with mismatched sex-specific cancers, for example, females with prostate cancer. These individuals were included in overall cancer rates but excluded from sex-specific cancer rates. Although there were proportionately more mismatched sex cases in the population with intellectual disabilities compared to the general population, the number of mismatches in the former was so small (<5) that excluding mismatched records did not have any meaningful impact on either rates or ratios. The number of records in the linked analysis data set was 583 264.

Data variables and management

Baseline demographics of age, sex, Scottish Index of Multiple Deprivation (SIMD 2016) quintile and living arrangements (intellectual disabilities group only) were taken from Scotland's 2011 Census (<https://www.scotlandscensus.gov.uk/about/2011-census/>). SIMD is a composite measure derived from geographical area of residence relating to socioeconomic status (<https://www.gov.scot/collections/scottish-index-of-multiple-deprivation-2020>). NRS death records were used to identify details of deaths, with the underlying cause of death defined internationally as the 'disease or injury which initiated the chain of morbid events leading directly to death'. Given concerns about the quality of recording on death certificate data on underlying cause of death, like others we chose also to combine the all-contributing causes of death (up to 10 additional causes) with cancer mentioned on the death certificate in any position. Presented cancer mortality results are those people who




Figure 1 Age structure of cohorts with number of people per 100 000 person-years and incidence of any cancer by group for (A) adults with intellectual disabilities and (B) general population, number of people categorised into age groups from Scotland's 2011 Census.

have died with cancer as underlying cause of death listed in position 1.

The Cancer Registry includes information on all new diagnoses of cancer occurring within Scotland. NRS death data and Cancer Registry include diagnostic codes from the International Classification of Disease 10th revision (ICD-10) and specific cancers were grouped accordingly (online supplemental table 1). The Cancer Registry holds data on tumour types using the International Classification of Diseases for Oncology (ICD-O). Scotland's Cancer Registry has high-quality robust population data; however, there is a necessary time delay to allow accrual of information. In the whole cohort, there were <0.5% discrepancies between the Cancer Registry and death certificate data, and data from the Cancer Registry were prioritised, for example, NRS death data coding for 'Colon unspecified cancer' and Cancer registry coding for 'Rectal cancer'. However, NRS deaths are updated daily and there were <1.0% cases of cancer-related mortality without available data from the Cancer Registry matching death certificate data.

Statistical analysis

Baseline characteristics were reported from the time of Scotland's 2011 Census. Cancer incidence and mortality rates were calculated from any newly diagnosed cancers (incidence) and cancer-related deaths (mortality) during the study period. Numbers reported are for cancer per person, with percentages calculated from the total number of cancers not person, as individuals with multiple cancers are included in different categories, for example, lung and breast cancer. Crude incidence and mortality rates (CMR) are reported per 100 000 person-years using the cancer diagnosis date/date of death and reflect the cancer burden faced by each group separately. Age-sex-standardised incidence rate ratios and mortality ratios (SIR/SMR) are reported with the general population as reference (indirectly standardised), with 95% CI. Ratios (SIR/SMR) higher than 1.0 indicate an increased risk for the population with intellectual disabilities, and

less than 1.0, a lower risk. Rates are reported per 100 000 person-years unless there are fewer than <5 cases where no calculation was attempted due to lack of reliability and cases are reported as <5 due to disclosure risk. Totals above 5 are similarly suppressed where providing the exact total would disclose the number below 5 for a specific sex in further tables (i.e. a suppression of <10 and <20 is also used). For cancer types that figures have been suppressed, percentages are not reported. All rates calculated from variables within 5–20 deaths are labelled as unreliable ('u') in line with the Office for National Statistics guidelines.⁵ Non-melanoma skin cancer (ICD-10 code C44) was excluded from statistical analyses of all cancers combined, due to incomplete incidence data capture, and in line with Public Health Scotland guidelines.²¹ One researcher (LMW) conducted the analyses, and a second researcher (FS) verified the coding for accuracy. All statistical analysis was conducted in Stata V.16.

Patient and public involvement

The Scottish Learning Disabilities Observatory (SLDO) has patient and public involvement in the steering committee where people with intellectual disabilities, carers and public members can guide, review and disseminate all research conducted.

RESULTS

Baseline characteristics of study cohort

The linked data sets consisted of 17 203 adults (136 590 person-years) with intellectual disabilities (with/without autism) and 566 061 adults (4 683 379 person-years) from the general population without intellectual disabilities or autism. As expected, the intellectual disabilities cohort contained a greater number of males, were on average younger and resided in more deprived areas. Table 1 shows the baseline characteristics of the whole cohort taken at the time of Scotland's 2011 Census and the cohort with any cancer diagnosis or cancer-related death. There were 3240 (18.8%) adults with intellectual disabilities who died

Table 2 Female cumulative cancer incidence (raw numbers (n), percentages (%), crude incidence rate (CIR) and standardised incidence rate ratio (SIR) with 95% CI)

Cancer category	Intellectual disabilities			General population			SIR (95% CI)
	N	%	CIR	N	%	CIR	
All incident cancers	419	100.0	542.5	23 116	100.0	809.4	0.79 (0.71 to 0.88)
Digestive organs	85	20.3	116.5	4192	18.1	148.3	0.96 (0.76 to 1.22)
Colorectal	42	10.0	61.3	2357	10.2	84.1	0.91 (0.66 to 1.27)
Oesophageal	9	2.1	13.8 u	364	1.6	13.8	1.20 (0.61 to 2.35) u
Stomach	9	2.1	13.8 u	317	1.4	12.2	1.25 (0.63 to 2.49) u
Liver	7	1.7	7.7 u	298	1.3	8.4	1.21 (0.48 to 3.05) u
Pancreas	5	1.2	7.7 u	474	2.1	18.5	0.53 (0.21 to 1.33) u
Breast	96	22.9	139.5	5573	24.1	214.0	0.75 (0.61 to 0.93)
Respiratory and intrathoracic	40	9.5	53.6	3498	15.1	124.1	0.55 (0.39 to 0.78)
Lung	34	8.1	52.1	3074	13.3	120.2	0.56 (0.39 to 0.80)
Haematopoietic	33	7.9	42.9	1475	6.4	48.0	0.98 (0.66 to 1.44)
Hodgkin's and non-Hodgkin's lymphoma	20	4.8	26.1 u	687	3.0	24.3	1.13 (0.69 to 1.84) u
Lymphoid leukaemia	5	1.2	7.7 u	179	0.8	4.7	1.52 (0.62 to 3.73) u
Myeloid leukaemia	<5			209	0.9	5.9	
Leukaemia of unspecified cell type	<5			8		0.3 u	
Female genital organs	72	17.2	102.7	2449	10.6	86.6	1.32 (1.03 to 1.70)
Body of uterus	39	9.3	55.2	995	4.3	36.6	1.63 (1.16 to 2.29)
Ovary	25	6.0	38.3	707	3.1	27.9	1.59 (1.05 to 2.42)
Vulva	<5			164	0.7	6.4	
Cervical	<5			349	1.5	13.7	
Metastatic cancer of unknown primary origin	27	6.4	27.6	756	3.3	22.8	1.70 (1.04 to 2.77)
Urinary tract	24	5.7	32.2	979	4.2	33.4	1.22 (0.78 to 1.90)
Kidney	16	3.8	24.5 u	430	1.9	16.8	1.85 (1.11 to 3.09) u
Bladder	7	1.7	7.7 u	373	1.6	13.7	0.70 (0.28 to 1.71) u
Lip, oral cavity and pharynx	8	1.9	10.7 u	379	1.6	13.7	0.86 (0.40 to 1.84) u
Central nervous system	9	2.1	6.1 u	276	1.2	9.4	0.69 (0.25 to 1.89) u
Melanoma (skin)	8	1.9	12.3 u	740	3.2	28.9	0.50 (0.24 to 1.05) u
<i>Non-melanoma skin</i>			75.3			209.7	0.44 (0.33 to 0.60)
Mesothelial and soft tissue	<5			230	1.0	7.3	
Thyroid and endocrine glands	<5			245	1.1	9.2	
Thyroid	<5			221	1.0	8.7	
Bone and articular cartilage	<5			37	0.2	0.6	

Non-melanoma skin cancers were not included in the rate calculations in the denominator. Figures in bold are statistically significant at the 5% level.

Numbers reported are for cancer incidence, with percentages calculated from the total number of cancers not person. CIR are reported per 100 000 person-years and SIR are age-standardised rate ratios.

U, unreliable age-sex-standardisation due to n<20 cases.

during the study, 435 (2.5%) were cancer-related mortalities, compared with 64 339 (11.4%) deaths in the general population with 18 678 (3.3%) cancer-related deaths. **Figure 1** shows the different age structures between the groups of adults with and without intellectual disabilities, and the cohorts with cancer. The population with intellectual disabilities is a younger cohort due to the prevailing 20 year premature mortality health inequality, and this

should be considered in the context of cancers, which are mostly age-related diseases.

Cancer incidence

Fewer adults with intellectual disabilities had a record of cancer (816 cancers in 796 people out of the 17 203 persons (4.7%)), compared with adults from the general population (43 775 cancers in 42 397 people out of the

Table 3 Male cumulative cancer incidence (raw numbers (n), percentages (%), crude incidence rate (CIR) and standardised incidence rate ratio (SIR) with 95% CI)

Cancer category	Intellectual disabilities			General population			SIR (95% CI)
	N	%	CIR	N	%	CIR	
All incident cancers	397	100.0	402.3	20 659	100.0	751.1	0.71 (0.64 to 0.80)
Digestive organs	135	34.0	144.6	5255	25.4	206.1	0.93 (0.77 to 1.13)
Colorectal	74	18.6	81.4	2733	13.2	106.8	0.99 (0.77 to 1.28)
Oesophageal	20	5.0	23.1 u	691	3.3	29.9	0.96 (0.59 to 1.56) u
Stomach	13	3.3	15.8 u	492	2.4	21.0	1.01 (0.57 to 1.80) u
Liver	7	1.8	4.9 u	535	2.6	20.1	0.35 (0.12 to 1.03) u
Pancreas	8	2.0	9.7 u	464	2.2	20.1	0.76 (0.36 to 1.61) u
Respiratory and intrathoracic	51	12.8	58.3	3682	17.8	144.7	0.57 (0.42 to 0.77)
Lung	42	10.6	49.8	3030	14.7	131.8	0.54 (0.39 to 0.75)
Haematopoietic	42	10.6	42.5	1900	9.2	69.2	0.80 (0.56 to 1.15)
Hodgkin's and non-Hodgkin's lymphoma	21	5.3	21.9	832	4.0	32.6	0.82 (0.50 to 1.34)
Lymphoid leukaemia	5	1.3	4.9 u	325	1.6	10.5	0.88 (0.31 to 2.52) u
Myeloid leukaemia	<5			223	1.1	7.0	
Leukaemia of unspecified cell type	<5			11	0.1	0.4 u	
Male genital organs	70	17.6	66.8	5231	25.3	195.8	0.49 (0.37 to 0.66)
Prostate	35	8.8	36.5	4425	21.4	184.1	0.37 (0.25 to 0.53)
Testicular	22	5.5	25.5	200	1.0	8.8	2.49 (1.58 to 3.91)
Metastatic cancer of unknown primary origin	30	7.6	28	622	3.0	19.2	2.08 (1.33 to 3.24)
Urinary tract	32	8.1	29.2	1685	8.2	61.5	0.55 (0.36 to 0.83)
Kidney	18	4.5	20.7 u	646	3.1	28.1	0.80 (0.49 to 1.31) u
Bladder	6	1.5	7.3 u	732	3.5	28.7	0.34 (0.15 to 0.77) u
Lip, oral cavity and pharynx	13	3.3	14.6 u	769	3.7	30.3	0.61 (0.33 to 1.12) u
Central nervous system	8	2.0	6.1 u	349	1.7	13.0	0.54 (0.21 to 1.38) u
Melanoma (skin)	9	2.3	10.9 u	676	3.3	29.1	0.43 (0.22 to 0.86) u
<i>Non-melanoma skin</i>			87.8			301.8	0.39 (0.30 to 0.49)
Mesothelial and soft tissue	<5			353	1.7	13.8	
Thyroid and endocrine glands	<5			96	0.5	3.8	
Thyroid	<5			76	0.4	3.3	
Bone and articular cartilage	<5			44	0.2	1.2	

Non-melanoma skin cancers were not included in the rate calculations in the denominator. Figures in bold are statistically significant at the 5% level.

Numbers reported are for cancer incidence, with percentages calculated from the total number of cancers not person. CIR are reported per 100 000 person-years and SIR are age-standardised rate ratios.

U, unreliable age-sex-standardisation due to n<20 cases.

566 061 persons (7.7%)). Cancer incidence for females is given in table 2, and table 3 for males. Standardised Incident Rate Ratio for total SIR=0.76 (0.70–0.82), female SIR=0.79 (0.71–0.88), male SIR=0.71 (0.64–0.80) (total incidence is given in online supplemental table 2). For women with intellectual disabilities, the most common diagnosis was breast (22.9% of all cancers among women), digestive (20.3%), specifically colorectal (10.0%) and female genital organs (17.2%), specifically body of the uterus (9.3%). For men with intellectual disabilities, the most common diagnosis was digestive (34.0% of all cancers among men), specifically colorectal (18.6%),

male genital organs (17.6%), specifically prostate cancer (8.8%) and respiratory organs (12.8%). Additionally, 12 (2.9%) people with, and 2290 (9.9%) without intellectual disabilities had cervical carcinoma-in-situ diagnosed.

Cancer mortality

During follow-up, cancer was the underlying cause of death for 435 (2.5%) of the 17 203 adults with intellectual disabilities and 18 678 (3.3%) of the 566 061 adults from the general population; SMR=1.20 (1.08 to 1.33), female SMR=1.34 (1.16 to 1.55) and male SMR=1.07 (0.92 to 1.24). Cancer mortality for

Table 4 Female cancer mortality (raw numbers (n), percentages (%), crude mortality rate (CMR) and standardised mortality rate ratio (SMR) with 95% CI), for underlying cause of death as cancer

Cancer category	Intellectual disabilities			General population sample			
	N	%	CMR	N	%	CMR	SMR (95% CI)
Number of underlying cause cancer deaths	212	100.0	353.3	9141	100.0	369.5	1.34 (1.16 to 1.55)
Digestive organs	47	22.2	78.3	2140	23.4	86.5	1.29 (0.95 to 1.75)
Colorectal	20	9.4	33.3u	846	9.3	34.2	1.49 (0.93 to 2.38) u
Oesophageal	7	3.3	11.7u	280	3.1	11.3	1.26 (0.57 to 2.75) u
Stomach	7	3.3	11.7u	230	2.0	9.3	1.58 (0.71 to 3.55) u
Pancreas	<5			401	4.4	16.2	
Liver	5	2.1	8.3u	167	1.8	6.8	1.86 (0.72 to 4.80) u
Respiratory and intrathoracic organs	30	14.2	50.0	2174	23.8	87.9	0.84 (0.57 to 1.23)
Lung	29	13.7	48.3	2137	23.4	86.4	0.84 (0.57 to 1.23)
Metastatic cancer of unknown primary origin	18	8.5	30.0u	481	5.3	19.4	2.50 (1.52 to 4.11) u
Female genital organs	29	13.7	48.3	704	7.7	28.5	2.34 (1.57 to 3.49)
Ovary	16	7.6	26.7u	335	3.7	13.5	2.86 (1.66 to 4.92) u
Body of Uterus	9	4.3	15.0u	217	2.4	8.8	2.11 (1.06 to 4.19) u
Cervical	<5			82	0.9	3.3	
Vulva	<5			43	0.5	1.7	
Urinary tract	12	5.7	20.0u	365	4.0	14.8	1.84 (1.02 to 3.31) u
Kidney	7	3.3	11.7u	134	1.5	5.4	2.85 (1.31 to 6.20) u
Bladder	5	2.4	8.3u	193	2.1	7.8	1.49 (0.60 to 3.70) u
Haematopoietic	11	5.2	18.3u	411	4.5	16.6	1.24 (0.67 to 2.29) u
Hodgkin's and Non-Hodgkin's lymphoma	8	3.8	13.3u	184	2.0	7.4	2.00 (0.97 to 4.12) u
Lymphoid leukaemia	<5			26	0.3	1.1	
Myeloid leukaemia	<5			90	1.0	3.6	
Leukaemia of unspecified cell type	<5			<5			
Breast	21	10.0	35	687	7.5	27.8	1.58 (1.00 to 2.52)
Lip, oral cavity and pharynx	<5			111	1.2	4.5	
Central nervous system	<5			157	1.7	6.4	
Mesothelial and soft tissue	<5			100	1.1	4.0	
Melanoma (skin)	<5			66	0.7	2.7	
<i>Non-melanoma skin</i>	<5			240	0.1	9.7	
Thyroid and other endocrine glands	<5			23	0.3	0.9	
Thyroid	<5			17	0.2	0.7u	
Bone and articular cartilage	<5			<5			

Non-melanoma skin cancers were not included in the rate calculations in the denominator. Figures in bold are statistically significant at the 5% level.
 CMR are reported per 100 000 person-years and SMR are age-standardised rate ratios.
 U, unreliable age-sex-standardisation due to n<20 cases.

females is shown in tables 4 and 5 for males, and total mortality is shown in online supplemental table 3.

Figure 2 plots trends in cancer incidence and mortality together with the most common cancers for each group, by sex. Standardised rate ratios comparing the population with and without intellectual disabilities show a clear trend of higher cancer deaths despite a lower or comparable incidence. For females this is most notable for cancers

of the female genital organs (SIR=1.32, SMR=2.34), specifically ovarian (SIR=1.59, SMR=2.86u), body of uterus cancers (SIR=1.63, SMR=2.11u), and breast cancer (SIR=0.75, SMR=1.58). For males, the disparity between incidence and mortality is highest for colorectal cancers (SMR=1.59), and haematopoietic cancers (SIR=0.80, SMR=1.26). Results regarding all-cause mortality findings are reported in online supplemental tables 3–6.

Table 5 Male cancer mortality (raw numbers (n), percentages (%), crude mortality rate (CMR) and standardised mortality rate ratio (SMR) with 95% CI), for underlying cause of death as cancer

Cancer category	Intellectual disabilities			General population			SMR (95% CI)
	N	%	CMR	N	%	CMR	
Number of underlying cause cancer deaths	223	100.0	291.2	9537	100.0	431.7	1.07 (0.92 to 1.24)
Digestive organs	68	30.5	88.8	2599	27.3	117.6	1.15 (0.88 to 1.50)
Colorectal	32	14.3	41.8	895	9.4	40.5	1.59 (1.08 to 2.33)
Oesophageal	15	6.7	19.6u	531	5.6	24.0	1.19 (0.67 to 2.13) u
Stomach	9	4.0	11.8u	332	3.5	15.0	1.23 (0.60 to 2.53) u
Pancreas	7	3.1	9.1u	389	4.1	17.6	0.85 (0.38 to 1.94) u
Liver	<5			328	3.4	14.9	
Respiratory and intrathoracic organs	36	16.1	47	2344	24.6	106.1	0.71 (0.49 to 1.01)
Lung	32	14.3	41.8	2231	23.4	101.0	0.66 (0.45 to 0.97)
Metastatic cancer of unknown primary origin	21	9.7	27.4	327	3.4	14.8	2.84 (1.76 to 4.58)
Urinary tract	14	6.3	18.3u	510	5.3	23.1	0.95 (0.54 to 1.66) u
Kidney	8	3.6	10.5u	180	1.9	8.2	1.38 (0.66 to 2.90) u
Bladder	5	2.2	6.5u	277	2.9	12.5	0.71 (0.28 to 1.80) u
Haematopoietic	15	6.7	19.6u	539	5.7	24.4	1.26 (0.71 to 2.23) u
Hodgkin's and non-Hodgkin's lymphoma	6	2.7	7.8u	219	2.3	9.9	1.09 (0.47 to 2.52) u
Lymphoid leukaemia	<5			49	0.5	2.2	
Myeloid leukaemia	<5			91	1.0	4.1	
Leukaemia of unspecified cell type	<5			<5			
Male genital organs	12	5.4	15.7u	767	8.0	34.8	1.10 (0.60 to 2.01) u
Prostate	10	4.5	13.1u	741	7.8	33.6	0.97 (0.51 to 1.87) u
Testicular	<5			9	10.0	0.4u	
Lip, oral cavity and pharynx	6	2.7	7.8u	256	2.7	11.6	0.79 (0.34 to 1.86) u
Central nervous system	<5			215	2.3	9.7	
Mesothelial and soft tissue	<5			186	2.0	8.4	
Melanoma (skin)	<5			88	0.9	4	
<i>Non-melanoma skin</i>	<5			466	0.2	21.1	
Thyroid and other endocrine glands	<5			12	0.1	0.5u	
Thyroid	<5			6	0.1%	0.3u	
Bone and articular cartilage	<5			14	0.1%	0.6u	

Non-melanoma skin cancers were not included in the rate calculations in the denominator. Figures in bold are statistically significant at 5% level.

CMR are reported per 100 000 person-years and SMR are age-standardised rate ratios.

U, unreliable age-sex-standardisation due to n<20 cases.

DISCUSSION

The population with intellectual disabilities had higher cancer mortality rates than incidence rates across all cancer types, indicating poorer outcomes. This is the first study to report cancer-related mortality within the context of cancer incidence comparing adults with and without intellectual disabilities. We report excess mortality regardless of whether the number of diagnosed cancers were lower, higher, or comparable to the general population. Particularly striking was our finding that metastatic cancer of unknown primary origin had significantly higher incidence (SIR=1.86) and mortality (SMR=2.64) in the

population with intellectual disabilities, demonstrating later presentation of cancer compared with the general population, potentially indicating a delay to diagnosis.

In terms of the most common cancer types, there are similarities and differences from the general population. Women with intellectual disabilities share the top two cancers with the general population (breast and colorectal), with female genital organ cancer being the third. Their incidence was higher for body of the uterus (SIR=1.63), ovarian (SIR=1.59) and kidney cancer (SIR=1.85u); and lower for breast cancer (SIR=0.75). Men with and without intellectual disabilities shared




Figure 2 Age-sex-standardised rate ratios of the most common cancer incidence and mortality comparing adults with and without intellectual disabilities for (A) females and (B) males. Note there is no result for testicular mortality ratio due to fewer than <5 cases and no calculation attempted due to lack of reliability. Additionally, metastatic cancers of unknown primary origin are not included in these figures as cancer categories are primary cancers.

common cancers; digestive (specifically colorectal), male genital organs, and respiratory cancers, but with variations in testicular (SIR=2.49), and prostate cancer rates (SIR=0.37). The limited available evidence from older comparator studies has some support for higher incident digestive, uterine and testicular cancers in people with intellectual disabilities,^{18 22} but not for metastatic cancers of unknown primary origin. However, recent evidence indicates that adults with intellectual disabilities have more advanced cancer at diagnosis and poorer survival.²³ This study reported a higher likelihood of preventable secondary cancers in people with intellectual disabilities; breast and colorectal, indicating that like our data, people with intellectual disabilities present later with cancer. However, this cross-sectional study reported a high rate of missing data (e.g. 33% of staging data for lung cancer in the intellectual disabilities, double that for the general population), and potential limitations in case identification of those with intellectual disabilities. Notably, our study reveals significantly higher rates of ovarian cancer in women with intellectual disabilities, a unique finding not previously reported.^{17 18} Similarly, in women with and without intellectual disabilities, comparable rates of breast cancer have previously been reported,^{17 18} but we found a statistically significant lower SIR. Breast cancer screening is crucial to avoid a proportion of breast cancer deaths through early treatment.^{10 24} However, in Scotland, women with intellectual disabilities were 45% less likely to participate in mammography screening, which may have contributed to lower detection rates.¹³ For men with intellectual disabilities, our results confirm lower prostate cancer incidence,^{17 18} and report higher testicular cancer incidence.²² While other cancers in our data could be compared with Patja and Sullivan, differences in study

context and size should be noted, as well as the inclusion of children in these earlier studies.

Adults with intellectual disabilities were less likely to be diagnosed with cancer but were disproportionately more likely to die from cancer (SMR=1.20). The observed mortality rates were consistently elevated compared with the expected rates. Similar findings were reported by Cuypers and colleagues (SMR=1.48), although their analysis included in-situ and benign neoplasms we intentionally excluded.⁷ Common cancer-related deaths were similar for women with and without intellectual disabilities, including digestive (specifically colorectal), respiratory and breast cancers. However, women with intellectual disabilities had higher mortality rates from female genital organ cancers (ovarian cancer SMR=2.86u, body of uterus SMR=2.11u), cancers of unknown primary origin (SMR=2.50u) and breast cancer (SMR=1.58). Common cancer-related deaths in men with intellectual disabilities mirrored the general population, including digestive (specifically colorectal), and respiratory cancers. However, men with intellectual disabilities experienced excess mortality from cancers of unknown primary origin (SMR=2.84) and colorectal cancer (SMR=1.59). These results confirm Cuypers *et al* findings who report excess mortality for female genital organs (SMR=1.70), breast (SMR=1.43), digestive (SMR=1.59) and cancers of unknown primary origin (SMR=2.48). However, they did not report SMRs for kidney, ovarian, and uterine cancers, which we observed to be higher in the population with intellectual disabilities.⁷ Although our colorectal rate (SMR=1.54) is lower than previously reported (between 1.24 and 2.56),^{7 9} there is a clear need to increase bowel screening participation for people with intellectual disabilities. Data from the Learning Disabilities Mortality

Review showed that 43% of people with intellectual disabilities who died with colorectal cancer were below the age threshold for screening (<60 years), suggesting a need to adjust public health programmes for this population.²⁴ This data suggest that public health approaches and messaging around breast, colorectal, and lung cancers are important for the population with intellectual disabilities (as well as for everyone else) and need to be accessible. Metastatic cancer of unknown primary origin results underscores the necessity for early detection and improved management of cancer. Factors contributing to higher SIRs and SMRs are likely complex, including self-care challenges, reliance on support workers to recognise cancer symptoms and signs, communication barriers, navigating healthcare services and inexperience of many healthcare workers working with adults with intellectual disabilities.

Two noteworthy points are our differences in respiratory and cervical mortality rates compared with Cuypers *et al.* Our lower lung cancer mortality rate (SMR=0.75) contrasts their SMR=1.24,⁷ but crude rates are similar (CMRs of 53 and 44.7). This suggests a lower smoking rate in the population with intellectual disabilities, but that the differing SMR directions is due to the lower general population rates in the Netherlands compared with Scotland. For cervical cancer, Cuypers *et al* report a high SMR=1.94 (with 17 deaths), whereas our small numbers were potentially disclosive. Our cervical carcinoma-in-situ data suggest that the rarity is not due to screening, with only 12 women with intellectual disabilities diagnosed. This may be related to reduced sexual activity, potentially lowering HPV infection rates and cervical cancer. While some women with intellectual disabilities may require support for cervical screening, our findings indicate other cancers contribute more significantly to excess cancer-related deaths. Assumptions about contributory behavioural and modifiable factors cannot be generalised between the population with and without intellectual disabilities. Indications in the data, such as living arrangement patterns, suggest the importance of exploring these factors in future research. Survival analyses are also indicated for common cancer types, as are studies on cancer staging at the time of presentation, cancer treatments and compliance. Such information is crucial for improving cancer outcomes in this population.

Our study's key strengths lie in the inclusion of a representative general population comparison group, and comprehensive coverage of Scotland's entire adult population with intellectual disabilities (both living in private households and communal establishments). This population is difficult to identify in administrative health data sets, and the use of Scotland's 2011 Census (with a high coverage rate) allows for self-identification. Robust record linkage also enhances data reliability and minimises bias. Prospective collection of data over nearly 9 years provided ample person-time for statistically well-powered analyses, allowing for a meaningful interpretation of mortality rates in the context of incidence. Limitations include

our inability to account for cancer incidence before the census date. Non-melanoma skin cancer incidence may be undercounted due to registry data-capture issues in these cancers, though mortality data are comprehensive. Death certificate data imprecision is possible, given multiple clinicians completion, but our dual-analysis approach mitigates differences and indeed both have similar interpretations. Despite using national data, low absolute case numbers for some cancers limit the study's power to detect differences.

CONCLUSIONS

Patterns of cancer incidence and mortality differ between adults with and without intellectual disabilities. Public health strategies must consider the unique needs of people with intellectual disabilities, emphasising accessibility. Promoting awareness of cancer symptoms among carers is crucial, especially for early detection. Support for bowel and breast screening programmes is essential, addressing lower uptake rates observed in this population. While cervical screening is provided, its impact on reducing cancer deaths may be limited. Clinicians need to be aware that cancers can present late in this population and provide preventive interventions on known risk factors to reduce incidence.

Author affiliations

¹Health Informatics Centre, University of Dundee School of Medicine, Dundee, UK

²Mental Health and Wellbeing, University of Glasgow School of Health and Wellbeing, Glasgow, UK

³University of St Andrews Faculty of Medicine, St Andrews, UK

⁴School of Health and Wellbeing, University of Glasgow, Glasgow, UK

⁵School of Cancer Sciences, University of Glasgow College of Medical Veterinary and Life Sciences, Glasgow, UK

⁶University of Glasgow Dental School, Glasgow, UK

X Laura McKernan Ward @lauramckward and Deborah Cairns @ScotLDO

Acknowledgements The authors would like to acknowledge the support of Public Health Scotland's electronic Data Research and Innovation Service (eDRIS) team involved in the provisioning and linkage of the data, and for the use of the Trusted Research Environment for analysis within the National Safe Haven.

Contributors LMW is the guarantor and accepts full responsibility for the finished work and the conduct of the study, had access to the data and controlled the decision to publish. LMW: conceptualisation, methodology, formal analysis, data curation, writing—original draft, project administration. S-AC: conceptualisation, writing—original draft, writing—reviewing and editing. FS: conceptualisation, methodology, formal analysis, data curation, writing—reviewing and editing. DM: conceptualisation, methodology, formal analysis, writing—reviewing and editing. MF: methodology, formal analysis, writing—reviewing and editing. CM: methodology, writing—reviewing and editing. KR: conceptualisation, writing—reviewing and editing. CH: methodology, writing—reviewing and editing. LH-M: data curation, writing—reviewing and editing. KD: writing—reviewing and editing. AH: project administration, writing—reviewing and editing. GS: methodology, writing—reviewing and editing. MT: supervision, writing—reviewing and editing. DC: conceptualisation, supervision, writing—reviewing and editing.

Funding Funding for the study includes the UK Medical Research council (grant MC_PC_17217), the Scottish Government via the Scottish Learning Disabilities Observatory (SLDO) and the Baily Thomas Charitable Fund.

Competing interests None declared.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data used in this study were available in the Scottish National Safe Haven (Project Number: 1819-0051), but as restrictions apply, this is not publicly available. Access to data may be granted on application to, and subject to approval by, the Public Benefit and Privacy Panel for Health and Social Care. Applications are coordinated by eDRIS (electronic Data Research and Innovation Service). The anonymised data used in this study was made available to accredited researchers only through the Public Health Scotland (PHS) eDRIS User agreement.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

ORCID iDs

Laura McKernan Ward <http://orcid.org/0000-0003-0880-0662>

Sally-Ann Cooper <http://orcid.org/0000-0001-6054-7700>

Katie Robb <http://orcid.org/0000-0002-1672-0411>

Catherine R Hanna <http://orcid.org/0000-0002-0907-7747>

Angela Henderson <http://orcid.org/0000-0002-6146-3477>

Maria Truesdale <http://orcid.org/0000-0003-3081-7858>

Deborah Cairns <http://orcid.org/0000-0002-2626-1554>

REFERENCES

- Maulik PK, Mascarenhas MN, Mathers CD, *et al*. Prevalence of intellectual disability: a meta-analysis of population-based studies. *Res Dev Disabil* 2011;32:419–36.
- O’Leary L, Cooper S-A, Hughes-McCormack L. Early death and causes of death of people with intellectual disabilities: a systematic review. *J Appl Res Intellect Disabil* 2018;31:325–42.
- Cooper S-A, Allan L, Greenlaw N, *et al*. Rates, causes, place and predictors of mortality in adults with intellectual disabilities with and without down syndrome: cohort study with record linkage. *BMJ Open* 2020;10:e036465.
- Hosking FJ, Carey IM, Shah SM, *et al*. Mortality among adults with intellectual disability in england: comparisons with the general population. *Am J Public Health* 2016;106:1483–90.
- Office for National Statistics. Avoidable mortality in the UK QMI. 2020.
- Ferlay J, Colombet M, Soerjomataram I, *et al*. Cancer statistics for the year 2020: an overview. *Int J Cancer* 2021;149:778–89.
- Cuyper M, Schalk BWM, Boonman AJN, *et al*. Cancer-related mortality among people with intellectual disabilities: a nationwide population-based cohort study. *Cancer* 2022;128:1267–74.
- Tyrer F, Morris R, Kiani R, *et al*. Mortality disparities and deprivation among people with intellectual disabilities in England: 2000–2019. *J Epidemiol Community Health* 2022;76:168–74.
- Glover G, Williams R, Heslop P, *et al*. Mortality in people with intellectual disabilities in England. *J Intellect Disabil Res* 2017;61:62–74.
- Ng N, Flygare Wallén E, Ahlström G. Mortality patterns and risk among older men and women with intellectual disability: a swedish national retrospective cohort study. *BMC Geriatr* 2017;17:269.
- Tyrer F, McGrother C. Cause-specific mortality and death certificate reporting in adults with moderate to profound intellectual disability. *J Intellect Disabil Res* 2009;53:898–904.
- Iezzoni LI. Cancer detection, diagnosis, and treatment for adults with disabilities. *Lancet Oncol* 2022;23:e164–73.
- McCowan C, McSkimming P, Papworth R, *et al*. Comparing uptake across breast, cervical and bowel screening at an individual level: a retrospective cohort study. *Br J Cancer* 2019;121:710–4.
- Sandberg M, Ahlström G, Kristensson J. Patterns of somatic diagnoses in older people with intellectual disability: a swedish eleven year case-control study of inpatient data. *J Appl Res Intellect Disabil* 2017;30:157–71.
- Satgé D, Axmon A, Trétarre B, *et al*. Cancer diagnoses among older people with intellectual disability compared with the general population: a national register study. *J Intellect Disabil Res* 2020;64:579–88.
- Liu Q, Adami H-O, Reichenberg A, *et al*. Cancer risk in individuals with intellectual disability in sweden: a population-based cohort study. *PLoS Med* 2021;18:e1003840.
- Patja K, Eero P, Iivanainen M. Cancer incidence among people with intellectual disability. *J Intellect Disabil Res* 2001;45:300–7.
- Sullivan SG, Hussain R, Threlfall T, *et al*. The incidence of cancer in people with intellectual disabilities. *Cancer Causes Control* 2004;15:1021–5.
- Cuyper M, Tobi H, Huijsmans CAA, *et al*. Disparities in cancer-related healthcare among people with intellectual disabilities: a population-based cohort study with health insurance claims data. *Cancer Med* 2020;9:6888–95.
- Cooper S-A, Henderson A, Kinnear D, *et al*. Cohort profile: scotland’s record-linkage e-cohorts of people with intellectual disabilities, and autistic people (SCIDA). *BMJ Open* 2022;12:e057230.
- Public Health Scotland. Cancer incidence and prevalence in scotland (to December 2019). 2021.
- Sasco AJ, Ah-Song R, Nishi M, *et al*. Testicular cancer and intellectual disability. *Int J Disabil Hum Dev* 2008;7.
- Mahar AL, Biggs K, Hansford RL, *et al*. Stage iv breast, colorectal, and lung cancer at diagnosis in adults living with intellectual or developmental disabilities: a population-based cross-sectional study. *Cancer* 2024;130:740–9.
- Heslop P, Cook A, Sullivan B, *et al*. Cancer in deceased adults with intellectual disabilities: english population-based study using linked data from three sources. *BMJ Open* 2022;12:e056974.

Supplementary Tables

S1. Cancer types categorised by ICD-10 codes from C00 – C97 Malignant Neoplasms.

ICD10 code category	ICD10 subcategory	Cancer area
C00-C14		Lip, oral cavity, & pharynx
C15-C26	C15 C16 C22 C18-C21 C25	Digestive organs Oesophageal Stomach Liver Colorectal Pancreas
C30-C39	C33-34	Respiratory & Intrathoracic organs Lung cancer
C40-C41		Bone & articular cartilage
C43-C44	C43 C44	Melanoma (skin) Other malignant neoplasms (non-melanoma)
C45-C49		Mesothelial & soft tissue
C50		Breast
C51-C58	C51 C53 C54-C55 C56	Female genital organs Vulva Cervical Uterus Ovary
C60-C63	C61 C62	Male genital organs Prostate Testicular
C64-C68	C64 C67	Urinary tract Kidney Bladder
C69-C72		Eye, brain & other parts of the CNS
C73-C75	C73	Thyroid and other endocrine glands Thyroid
C76-C80		Metastatic cancer of unknown primary origin (ill-defined, secondary, & unspecified sites)
C81-C96	C81 - C85 C91 C92 C96	Stated or presumed to be primary, of lymphoid, haematopoietic, and related tissue Hodgkin's & Non-Hodgkin's lymphoma Lymphoid leukaemia Myeloid leukaemia Leukaemia of unspecified cell type

S2. Cumulative cancer incidence (raw numbers [n], percentages [%], Crude Incidence Rate [CIR], and Standardized Incidence Rate Ratio [SIR with 95% Confidence Interval [CI]]). Numbers reported are for cancer incidence, with percentages calculated from the total number of cancers not person. CIR are reported per 100,000 person-years and SIR are age- sex- standardised rate ratios.

Cancer category	Intellectual Disabilities (n=17,203)			General Population (n=566,061)			SIR (95% CI)
	n	%	CIR	n	%	CIR	
All incident cancers	816*	100.0%	464.3	43,775*	100.0%	781.8	0.76 (0.70, 0.82)
Digestive organs	220	26.9%	132.2	9,447	21.5%	175.6	0.95 (0.81, 1.10)
Colorectal	116	14.2%	72.5	5,090	11.6%	94.8	0.96 (0.78, 1.17)
Oesophageal	29	3.5%	19	1,055	2.4%	21.4	1.04 (0.70, 1.55)
Stomach	22	2.7%	14.9	809	1.8%	16.4	1.11 (0.71, 1.72)
Liver	14	1.7%	6.1u	833	1.9%	13.9	0.63 (0.31, 1.27)u
Pancreas	13	1.6%	8.8u	938	2.1%	19.3	0.64 (0.36, 1.15)u
Respiratory & Intrathoracic	91	11.1%	56.3	7,180	16.4%	133.8	0.56 (0.45, 0.70)
Lung	76	9.3%	50.8	6,104	13.9%	125.7	0.55 (0.43, 0.70)
Haematopoietic	75	9.2%	42.7	3,375	7.7%	58.0	0.88 (0.68, 1.14)
Hodgkin's & Non-Hodgkin's lymphoma	41	5.0%	23.7	1,519	3.5%	28.2	0.96 (0.68, 1.36)
Lymphoid leukaemia	10	1.2%	6.1u	504	1.1%	7.4	1.09 (0.54, 2.20)u
Myeloid leukaemia	5	0.6%	2.7u	432	1.0%	6.4	0.62 (0.21, 1.80)u
Leukaemia of unspecified cell type	<5	0.0%		19	0.0%	0.4u	
Metastatic cancer of unknown primary origin	57	7.0%	27.8	1,378	3.1%	21.1	1.86 (1.34, 2.60)
Urinary tract	56	6.8%	30.5	2,664	6.1%	46.7	0.80 (0.59, 1.09)
Kidney	34	4.2%	22.4	1,076	2.5%	22.2	1.22 (0.85, 1.76)
Bladder	13	1.6%	7.5u	1,105	2.5%	20.8	0.46 (0.25, 0.85)u
Lip, oral cavity & pharynx	21	2.6%	12.9	1,148	2.6%	21.6	0.69 (0.43, 1.11)
Central Nervous System	17	2.1%	6.1u	625	1.4%	11.1	0.60u (0.30, 1.21)u
Melanoma (skin)	17	2.1%	11.52u	1,416	3.2%	29.0	0.47 (0.28, 0.78)u
Non-melanoma skin cancer			82.3			253.1	0.41 (0.34, 0.50)
Mesothelial and soft tissue	6	0.7%	3.4u	583	1.3%	10.4	0.38 (0.15, 0.99)u
Thyroid & endocrine glands	5	0.6%	3.4u	341	0.8%	6.7	0.60 (0.24, 1.48)u
Thyroid	<5			297	0.7%	6.1	
Bone & articular cartilage	<5			81	0.2%	0.9	

* This figure excludes non-melanoma skin cancers. Figures in bold are statistically significant at 5% level.

U: unreliable age- sex- standardisation due to n<20 cases.

S3. Cancer mortality (raw numbers [n], percentages [%], Crude Mortality Rate [CMR], Standardized Mortality Ratios [SMR] with 95% Confidence Intervals [CI]), for underlying cause of death as cancer. CMR are reported per 100,000 person-years and SMR are age- sex- standardised rate ratios.

Cancer category	Intellectual Disabilities (n=17,203)			General Population (n=566,061)			SMR (95% CI)
	n	%	CMR	n	%	CMR	
Number of main-cause cancer deaths	435	100.0%	318.5	18,678	100.0%	398.8	1.20 (1.08, 1.33)
Digestive organs	115	26.4%	84.2	4,739	25.4%	101.2	1.21 (0.99, 1.48)
Colorectal	52	12.0%	38.1	1,741	9.3%	37.2	1.54 (1.13, 2.08)
Oesophageal	22	5.1%	16.1	811	4.3%	17.3	1.22 (0.76, 1.93)
Stomach	16	3.7%	11.7u	562	3.0%	12.0	1.38 (0.80, 2.35)u
Pancreas	<20		8.1u	790	4.2%	16.9	0.74 (0.39, 1.42)u
Liver	<10		5.1u	495	2.7%	10.6	0.76 (0.34, 1.72)u
Respiratory & Intrathoracic organs	66	15.2%	48.3	4,518	24.2%	96.5	0.77 (0.59, 1.00)
Lung	61	14.0%	44.7	4,368	23.4%	93.3	0.75 (0.57, 0.98)
Metastatic cancer of unknown primary origin	39	9.0%	28.6	808	4.3%	17.3	2.64 (1.86, 3.74)
Urinary tract	26	6.0%	19.0	875	4.7%	18.7	1.32 (0.87, 2.00)
Kidney	15	3.4%	11.0u	314	1.7%	6.7	2.01 (1.16, 3.49)u
Bladder	10	2.3%	7.3u	470	2.5%	10.0	1.03 (0.54, 1.99)u
Haematopoietic	26	6.0%	19.0	950	5.1%	20.3	1.25 (0.82, 1.90)
Hodgkin's & Non-Hodgkin's lymphoma	14	3.2%	10.3u	403	2.2%	8.6	1.51 (0.87, 2.60)u
Lymphoid leukaemia	<5			75	0.4%	1.6	
Myeloid leukaemia	<5			181	1.0%	3.9	
Leukaemia of unspecified cell type	<5			<5			
Lip, oral cavity & pharynx	<20		6.6u	367	2.0%	7.8	0.96 (0.48, 1.95)u
Central Nervous System	7	1.6%	5.1u	372	2.0%	7.9	0.76 (0.34, 1.70)u
Mesothelial and soft tissue	<5			286	1.5%	6.1	
Melanoma (skin)	<5			154	0.8%	3.3	
Non-melanoma skin	<5			706	0.1%	15.1	
Thyroid & other endocrine glands	<5			35	0.2%	0.8	
Thyroid	<5			23	0.1%	0.5	
Bone & articular cartilage	<5			<20		0.4u	

*The total number of cancers reported here is slightly lower than the actual number in the dataset due to mismatched sex (see section 2.1). This figure also excludes non-melanoma skin cancers. Figures in bold are statistically significant at 5% level. U: unreliable age- sex- standardisation due to n<20 cases.

S4. All-cause cancer mortality (raw numbers [n], percentages [%], Crude Mortality Rate [CMR], Standardized Mortality Ratios [SMR] with 95% Confidence Intervals [CI]), for all-cause of death as cancer. CMR are reported per 100,000 person-years and SMR are age- sex- standardised rate ratios.

Cancer category	Intellectual Disabilities (n=17,203)			General Population (n=566,061)			SMR (95% CI)
	n	%	CMR	n	%	CMR	
Number of all-cause cancer deaths	537	100.0%	393.2	22,467	100.0%	479.7	1.29 (1.17, 1.41)
Digestive organs	160	29.8%	117.1	6,429	28.6%	137.3	1.26 (1.06, 1.50)
Colorectal	70	13.0%	51.3	2,694	12.0%	57.5	1.37 (1.06, 1.78)
Oesophageal	25	4.7%	18.3	898	4.0%	19.2	1.20 (0.77, 1.86)
Stomach	20	3.7%	14.6u	646	2.9%	13.8	1.47u (0.92, 2.37)u
Liver	14	2.6%	10.3u	729	3.2%	15.6	1.04u (0.59, 1.85)u
Pancreas	<20		8.8u	847	3.8%	18.1	0.80u (0.43, 1.50)u
Respiratory & Intrathoracic organs	79	14.7%	57.8	5,880	26.2%	125.6	0.74 (0.59, 0.94)
Lung	67	2.5%	49.1	5,005	22.3%	106.9	0.74 (0.57, 0.96)
Unknown primary origin (metastases)	57	10.6%	41.7	1,284	5.7%	27.4	2.53 (1.90, 3.38)
Lymphoid, haematopoietic & related tissue	46	8.6%	33.7	1,824	8.1%	39.0	1.23 (0.90, 1.69)
Hodgkin's & Non-Hodgkin's lymphoma	24	4.5%	17.6	674	3.0%	14.4	1.72 (1.11, 2.66)
Lymphoid leukaemia	<10		4.4u	274	1.2%	5.9	1.30u (0.54, 3.14)u
Myeloid leukaemia	5	0.9%	3.7u	324	1.4%	6.9	0.80u (0.29, 2.20)u
Leukaemia of unspecified cell type	<5			5	0.0%	0.1u	
Urinary tract	44	8.2%	32.2	1,580	7.0%	33.7	1.37 (0.99, 1.89)
Kidney	22	4.1%	16.1	451	2.0%	9.6	2.14 (1.36, 3.36)
Bladder	13	2.4%	9.5u	709	3.2%	15.1	1.04u (0.58, 1.89)u
Central Nervous System	15	2.8%	11.0u	492	2.2%	10.5	1.08u (0.63, 1.87)u
Lip, oral cavity & pharynx	13	2.4%	9.5u	581	2.6%	12.4	1.04u (0.57, 1.88)u
Melanoma (skin)	6	1.1%	4.4u	280	1.2%	6.0	1.36u (0.57, 3.28)u
Non-melanoma skin	36	0.2%	89.3	2,805	0.5%	257.3	0.50 (0.41, 0.61)
Mesothelial and soft tissue	<5			422	1.9%	9.0	
Thyroid & other endocrine glands	<5			73	0.3%	1.6	
Thyroid	<5			39	0.2%	0.8	
Bone and articular cartilage	<5			62	0.3%	1.3	

*The total number of cancers reported here is slightly lower than the actual number in the dataset due to mismatched sex (see section 2.1 for more detail). This figure also excludes non-melanoma skin cancers. Figures in bold are statistically significant at 5% level.

S5. Female all-cause cancer mortality (raw numbers [n], percentages [%], Crude Mortality Rate [CMR], Standardized Mortality Ratios [SMR] with 95% Confidence Intervals [CI]), for all-cause of death as cancer. CMR are reported per 100,000 person-years and SMR are age- standardised rate ratios.

Cancer category	Intellectual Disabilities			General Population			SMR (95% CI)
	n	%	CMR	n	%	CMR	
Number of all-cause cancer deaths	263	100.0%	438.3	10,860	100.0%	438.9	1.44 (1.26, 1.64)
Digestive organs	62	23.6%	103.3	2,857	26.3%	115.5	1.30 (1.00, 1.70)
Colorectal	27	10.3%	45	1,258	11.6%	50.9	1.35 (0.90, 2.03)
Oesophageal	7	2.7%	11.7u	312	2.9%	12.6	1.13 (0.52, 2.46)u
Stomach	8	3.0%	13.3u	259	2.4%	10.5	1.59 (0.75, 3.36)u
Liver	7	2.7%	11.7u	271	2.5%	11	1.64 (0.75, 3.61)u
Pancreas	<5			430	4.0%	17.4	
Respiratory & Intrathoracic organs	36	13.7%	60	2,818	25.9%	113.9	0.79 (0.56, 1.11)
Lung	30	11.4%	50	2,441	22.5%	98.7	0.77 (0.53, 1.13)
Metastatic cancers of unknown primary origin	27	10.3%	45	716	6.6%	28.9	2.50 (1.66, 3.76)
Haematopoietic	19	7.2%	31.7u	785	7.2%	31.7	1.32 (0.81, 2.14)u
Hodgkin's & Non-Hodgkin's lymphoma	13	4.9%	21.7u	294	2.7%	11.9	2.31 (1.29, 4.16)u
Lymphoid leukaemia	<5			104	1.0%	4.2	
Myeloid leukaemia	<5			159	1.5%	6.4	
Leukaemia of unspecified cell type	<5			<5			
Urinary tract	17	6.5%	28.3u	591	5.4%	23.9	1.78 (1.08, 2.94)u
Kidney	9	3.4%	15.0u	179	1.6%	7.2	2.89 (1.46, 5.72)u
Bladder	7	2.7%	11.7u	261	2.4%	10.6	1.87 (0.85, 4.12)u
Female genital organs	44	16.8%	73.3	1,089	10.0%	44	2.22 (1.61, 3.08)
Body of Uterus	19	7.3%	31.7u	346	3.2%	14	3.00 (1.84, 4.90)u
Ovary	18	6.9%	30.0u	374	3.4%	15.1	2.75 (1.65, 4.60)u
Vulva	<5			61	0.6%	2.5	
Cervical	<5			98	0.9%	4	
Breast	43	16.4%	71.7	1,247	11.5%	50.4	2.07 (1.50, 2.87)
Male genital organs							
Prostate							
Testicular							
Central Nervous System	9	3.4%	15.0u	209	1.9%	8.5	1.73 (0.87, 3.44)u
Lip, oral cavity & pharynx	5	1.9%	8.3u	174	1.6%	7	1.53 (0.62, 3.82)u
Melanoma (skin)	<5			115	1.1%	4.7	
Non-melanoma skin	13	0.2%	81.7	1,110	0.4%	213.1	0.53 (0.39, 0.72)u
Mesothelial and soft tissue	<5			161	1.5%	6.5	
Thyroid & other endocrine glands	<5			46	0.4%	1.9	
Thyroid	<5			27	0.2%	1.1	
Bone and articular cartilage	<5			28	0.3%	1.1	

Note: non-melanoma skin cancers were not included in the rates calculations in the denominator. Figures in bold are statistically significant at 5% level.
U: unreliable age- sex- standardisation due to n<20 cases.

S6. Male all-cause cancer mortality (raw numbers [n], percentages [%], Crude Mortality Rate [CMR], Standardized Mortality Ratios [SMR] with 95% Confidence Intervals [CI]), for all-cause of death as cancer. CMR are reported per 100,000 person-years and SMR are age- standardised rate ratios.

Cancer category	Intellectual Disabilities			General Population			SMR (95% CI)
	n	%	CMR	n	%	CMR	
Number of all-cause cancer deaths	274	100.0%	357.8	11,607	100.0 %	525.4	1.14 (1.00, 1.30)
Digestive organs	98	35.8%	128	3,572	30.8%	161.7	1.23 (0.99, 1.54)
Colorectal	43	15.7%	56.2	1,436	12.4%	65	1.39 (0.99, 1.94)
Oesophageal	18	6.6%	23.5u	586	5.0%	26.5	1.24 (0.73, 2.10)u
Stomach	12	4.4%	15.7u	387	3.3%	17.5	1.40 (0.76, 2.58)u
Liver	7	2.6%	9.1u	458	3.9%	20.7	0.69 (0.30, 1.56)u
Pancreas	8	2.9%	10.5u	417	3.6%	18.9	1.02 (0.47, 2.21)u
Respiratory & Intrathoracic organs	43	15.7%	56.2	3,062	26.4%	138.6	0.70 (0.51, 0.97)
Lung	37	13.5%	48.3	2,564	22.1%	116.1	0.71 (0.50, 1.02)
Metastatic cancers of unknown primary origin	30	10.9%	39.2	568	4.9%	25.7	2.58 (1.73, 3.84)
Haematopoietic	27	9.9%	35.3	1,039	9.0%	47	1.17 (0.77, 1.78)
Hodgkin's & Non-Hodgkin's lymphoma	11	4.0%	14.4u	380	3.3%	17.2	1.26 (0.65, 2.42)u
Lymphoid leukaemia	5	1.8%	6.5u	170	1.5%	7.7	1.88 (0.72, 4.91)u
Myeloid leukaemia	<5			165	1.4%	7.5	
Leukaemia of unspecified cell type	<5			<5			
Urinary tract	27	9.9%	35.3	989	8.5%	44.8	1.12 (0.74, 1.70)
Kidney	13	4.7%	17.0u	272	2.3%	12.3	1.64 (0.92, 2.92)u
Bladder	6	2.2%	7.8u	448	3.9%	20.3	0.56 (0.24, 1.30)u
Male genital organs	37	13.6%	48.3	1,957	16.9%	88.7	1.29 (0.91, 1.83)
Prostate	22	8.1%	28.7	1,379	11.9%	62.5	1.24 (0.80, 1.92)
Testicular	<5			15	0.1%	0.7u	
Central Nervous System	6	2.2%	7.8u	283	2.4%	12.8	0.61 (0.26, 1.46)u
Lip, oral cavity & pharynx	8	2.9%	10.5u	407	3.5%	18.4	0.82 (0.37, 1.81)u
Melanoma (skin)	<5			165	1.4%	7.5	
Non-melanoma skin	23	0.2%	95.3	1,695	0.6%	306.8	0.47 (0.37, 0.61)
Mesothelial and soft tissue	<5			261	2.2%	11.8	
Thyroid & other endocrine glands	<5			27	0.2%	1.2	
Thyroid	<5			12	0.1%	0.5u	
Bone and articular cartilage	<5			34	0.3%	1.5	

Note: non-melanoma skin cancers were not included in the rates calculations in the denominator. Figures in bold are statistically significant at 5% level.

U: unreliable age- sex- standardisation due to n<20 cases.